News
At ASCO, Astra Zeneca reported that its drug Enhertu stalled the growth of tumors by more than a year in women with the most common form of metastatic breast cancer.
References: Enhertu® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease ...
Enhertu has been called a breakthrough in breast cancer treatment. While it doesn’t cure HER2 breast cancer, research shows that it provides patients with more time. According to the National Library ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results